Cryo-Cell International, a pioneer in private umbilical cord blood and tissue cryogenic storage, reported a modest 2% revenue decline in Q3 2026 driven by processing and storage fees. The company continues to operate FDA-compliant, AABB/FACT-accredited facilities managing over 250,000 specimens globally. However, the termination of its Duke University licensing agreement in mid-2025 has paused its clinical therapy development initiatives, posing strategic uncertainty. Financing remains manageable with debt refinements, but competitive dynamics from public banks and regulatory complexity remain key challenges. Monitoring customer retention, new specimen volume, and resolution of the Duke dispute will be critical for business momentum.